May 23, 2014
1 min read

Novartis reports 2014 Q1 sales, profit growth

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Novartis reported a 1% increase in net sales to $14 billion in the first quarter of 2014, according to a press release.

“Novartis delivered a solid quarter, with all divisions contributing to growth. We made progress in innovation, including [European Union] and U.S. approval of Xolair in chronic spontaneous urticaria and significant milestones for Bexsero,” Joseph Jimenez, CEO of Novartis, said in the release.

Alcon net sales were reported at $2.6 billion, marking a 3% increase from 2013. Surgical performance increased 6%, driven by equipment growth, and vision care increased 4% from sales in contact lenses, the release said.

Alcon’s operating income was $380 million, an 8% decrease from 2013, and core operating income was reported at $925 million, a 2% decrease from 2013.